Table 3.
Clinical-pathological data of lung squamous cell carcinoma (LUSC) from the TCGA dataset.
| Characteristics | Total | Characteristics | Total |
|---|---|---|---|
| All Stages | Non-Metastatic Disease | ||
| Cohort size (n) | 571 | 141 | |
| Age at diagnosis Mean ± SD |
67.65 ± 8.58 | Age at diagnosis Mean ± SD |
65.91 ± 8.66 |
| Sex | Sex | ||
| Male | 424 (74.3%) | Male | 112 (79.4%) |
| Female | 147 (25.7%) | Female | 29 (20.6%) |
| Race | Race | ||
| White | 402 (70.4%) | White | 124 (87.9%) |
| Black or African American | 40 (7%) | Black or African American | 4 (2.8%) |
| Asian | 10 (1.8%) | Asian | 4 (2.8%) |
| NA | 119 (20.8%) | NA | 9 (6.4%) |
| Number of packs/year Mean ± SD |
53.62 ± 32.12 | Number of packs/year Mean ± SD |
49.29 ± 25.24 |
| Stage of disease | Stage of disease | ||
| Stage I | 5 (0.9%) | Stage IA | 29 (20.6%) |
| Stage IA | 107 (18.7%) | Stage IB | 40 (28.4%) |
| Stage IB | 172 (30.1%) | Stage IIA | 30 (21.3%) |
| Stage II | 3 (0.5%) | Stage IIB | 24 (17%) |
| Stage IIA | 75 (13.1%) | Stage IIIA | 18 (12.8%) |
| Stage IIB | 108 (18.9%) | ||
| Stage III | 3 (0.5%) | ||
| Stage IIIA | 66 (11.6%) | ||
| Stage IIIB | 21 (3.7%) | ||
| Stage IV | 7 (1.2%) | ||
| NA | 4 (0.7%) | ||
SD, standard deviation.